The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study.

Mutlu HizalBurak BilginNail PaksoyÖzgür AçıkgözAhmet SezerMustafa GürbüzNaziye AkŞebnem YücelMurat AyhanCihan ErolAykut DemirkıranNil Molinas MandelAbdallah Shbairİvo GökmenTuğba BaşoğluSemra PaydaşAtike Gökçen DemirayYakup İriağaçTeoman ŞakalarEsra ZeynelgilAli Murat TatlıAykut BahçeciDeniz Can GüvenBurcu CanerAlper CanAhmet GülmezYusuf KarakaşBülent YalçınAhmet DemirkazıkAhmet BiliciAdnan AydınerPerran Fulden YumukMehmet Ali Nahit Şendur

Published in: Journal of cancer research and clinical oncology (2021)

Osimertinib is a highly effective option in second- or third-line treatment of NSCLC patients with T790M mutation, with a favorable safety profile.

Keyphrases

advanced non small cell lung cancer
epidermal growth factor receptor
small cell lung cancer
palliative care
tyrosine kinase
combination therapy
replacement therapy
smoking cessation